These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33492637)

  • 1. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
    Devarasetti PK; Rajasekhar L; Baisya R; Sreejitha KS; Vardhan YK
    Immunol Res; 2021 Feb; 69(1):18-25. PubMed ID: 33492637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
    Pang NY; Pang AS; Chow VT; Wang DY
    Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
    Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
    J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
    Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
    Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
    Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
    Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of convalescent plasma according to blood groups in COVID-19 patients.
    Hacibekiroğlu T; Kalpakçı Y; Genç AC; Hacibekiroğlu İ; Sunu C; Saricaoğlu A; Tomak Y; Karabay O; Köroğlu M
    Turk J Med Sci; 2021 Feb; 51(1):45-48. PubMed ID: 32950044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
    Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
    Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
    Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 20. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.